BALDUZZI ADRIANA CRISTINA

Saglio, F., Pagliara, D., Zecca, M., Balduzzi, A., Cattoni, A., Prete, A., et al. (2024). Long-term complications after allogeneic hematopoietic stem cell transplantation for pediatric patients with acute leukemia or myelodysplastic syndrome given either a Treosulfan- or a Busulfan-based conditioning regimen: results of an AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) retrospective study. TRANSPLANTATION AND CELLULAR THERAPY [10.1016/j.jtct.2023.12.671]. Detail

Bader, P., Poetschger, U., Dalle, J., Moser, L., Balduzzi, A., Ansari, M., et al. (2024). Low rate of nonrelapse mortality in under 4-year-olds with ALL given chemo-conditioning for HSCT: Phase III FORUM study. BLOOD ADVANCES, 8(2), 416-428 [10.1182/bloodadvances.2023010591]. Detail

Molinari, S., Fossati, C., Nicolosi, M., Di Marco, S., Faraguna, M., Limido, F., et al. (2024). Endocrine, auxological and metabolic profile in children and adolescents with Down syndrome: from infancy to the first steps into adult life. FRONTIERS IN ENDOCRINOLOGY, 15 [10.3389/fendo.2024.1348397]. Detail

Cattoni, A., Nicolosi, M., Capitoli, G., Gadda, A., Molinari, S., Louka, S., et al. (2023). Pubertal attainment and Leydig cell function following pediatric hematopoietic stem cell transplantation: a three-decade longitudinal assessment. FRONTIERS IN ENDOCRINOLOGY, 14 [10.3389/fendo.2023.1292683]. Detail

Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., et al. (2023). Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. BLOOD, 142(10), 865-877 [10.1182/blood.2023020578]. Detail